Evidence map›Paper›PMID 38700632›Full record

ArticleDigestive diseases and sciences2024

An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients.

Aaron P Thrift, Theresa H Nguyen Wenker, Kyler Godwin, Maya Balakrishnan, Hao T Duong, Rohit Loomba, Fasiha Kanwal, Hashem B El-Serag

Abstract read
In one paragraph

Article in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aaron P ThriftSection of Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX, USA.
Theresa H Nguyen WenkerSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Cambridge Street, Houston, TX, 7200, USA.
Kyler GodwinHouston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.
Maya BalakrishnanSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Cambridge Street, Houston, TX, 7200, USA.
Hao T DuongSection of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Rohit LoombaDivision of Epidemiology, Department of Family Medicine and Public Health, University of California at San Diego, San Diego, CA, USA.
Fasiha KanwalSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Cambridge Street, Houston, TX, 7200, USA.
Hashem B El-SeragSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Cambridge Street, Houston, TX, 7200, USA. hasheme@bcm.edu.ORCID http://orcid.org/0000-0001-5964-7579

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Hashem B El-Serag · 2001 to 2026
$28.3M
Pediatric Trials in Non-Alcoholic Steatohepatitis (NASH)U01DK061734 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2002 to 2026
$24.4M
Translational Research Support CoreP30ES030285 · NIEHS · BAYLOR COLLEGE OF MEDICINE · PI Cheryl L. Walker · 2019 to 2026
$14.7M
Tissue-specific roles of FXR in CVD and NASHP01HL147835 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT · 2020 to 2024
$12.2M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
HIV MASLD Clinical Research Network (HCRN)R01DK121378 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI NAGA P CHALASANI, ROHIT LOOMBA · 2020 to 2026
$8.7M
Risk Stratification for and Early Detection of Liver CancerU01CA230997 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Jagpreet Chhatwal, Hashem B El-Serag · 2018 to 2026
$6.4M
Novel IL-23 inhibitor for the treatment of alcohol associated liver diseaseU01AA029019 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KISSELEVA, TATIANA, LOOMBA, ROHIT · 2020 to 2024
$3.7M
Genome-Wide Association Study (GWAS) in Hepatocellular Carcinoma (HCC)R01CA186566 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMOS, CHRISTOPHER I., HASSAN, MANAL METWALLY · 2015 to 2019
$3.6M
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United StatesU01CA230694 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2018 to 2022
$3.5M
QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLDR01DK106419 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOOMBA, ROHIT, SIRLIN, CLAUDE B · 2015 to 2019
$3.4M
Cancer Prevention and Research Institute of Texas RP150587Cancer Prevention and Research Institute of Texas RP200537Center for Innovations in Quality, Effectiveness and Safety CIN 13-413CSRD VA I01 CX001616Gulf Coast Center for Precision and Environmental Health P30ES030285NCATS NIH HHS 5UL1TR001442NCATS NIH HHS UL1 TR001442NCI NIH HHS R01 CA186566NCI NIH HHS U01 CA230694NCI NIH HHS U01 CA230997NHLBI NIH HHS P01 HL147835NHLBI NIH HHS P01HL147835NIAAA NIH HHS U01 AA029019NIAAA NIH HHS U01AA029019NIDDK NIH HHS P30 DK120515NIDDK NIH HHS P30DK120515NIDDK NIH HHS P30 DK 56338NIDDK NIH HHS R01DK106419NIDDK NIH HHS R01DK121378NIDDK NIH HHS R01DK124318NIDDK NIH HHS T32 DK083266NIDDK NIH HHS U01DK061734NIDDK NIH HHS U01DK130190NIEHS NIH HHS P30 ES030285NIMHD NIH HHS K23 MD016955NIMHD NIH HHS K23MD016955U.S. Department of Veterans Affairs 5I01CX001616-04
6 · The paper itself

Abstract

backgroundOne challenge for primary care providers caring for patients with nonalcoholic fatty liver disease is to identify those at the highest risk for clinically significant liver disease.

aimTo derive a risk stratification tool using variables from structured electronic health record (EHR) data for use in populations which are disproportionately affected with obesity and diabetes.

methodsWe used data from 344 participants who underwent Fibroscan examination to measure liver fat and liver stiffness measurement [LSM]. Using two approaches, multivariable logistic regression and random forest classification, we assessed risk factors for any hepatic fibrosis (LSM > 7 kPa) and significant hepatic fibrosis (> 8 kPa). Possible predictors included data from the EHR for age, gender, diabetes, hypertension, FIB-4, body mass index (BMI), LDL, HDL, and triglycerides.

resultsOf 344 patients (56.4% women), 34 had any hepatic fibrosis, and 15 significant hepatic fibrosis. Three variables (BMI, FIB-4, diabetes) were identified from both approaches. When we used variable cut-offs defined by Youden's index, the final model predicting any hepatic fibrosis had an AUC of 0.75 (95% CI 0.67-0.84), NPV of 91.5% and PPV of 40.0%. The final model with variable categories based on standard clinical thresholds (i.e., BMI ≥ 30 kg/m

conclusionsOur results demonstrate that standard thresholds for clinical risk factors/biomarkers may need to be modified for greater discriminatory ability among populations with high prevalence of obesity and diabetes.

Indexed as

Electronic Health RecordsLiver CirrhosisNon-alcoholic Fatty Liver DiseasePrimary Health CareAdultAgedBody Mass IndexElasticity Imaging TechniquesFemaleHumansMaleMiddle AgedObesityPredictive Value of TestsRisk AssessmentRisk FactorsFatty liverLiver cancerObesityVeterans

Identifiers

PMID38700632
PMCPMC11258165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.